Life Sciences Real Estate & the Rumour of Its Decline
- Galileo Labs
- 3 days ago
- 1 min read
When venture capital flooded into life sciences between 2020 and 2023, the US and UK responded very differently. America built. Britain planned. When funding conditions tightened, those differences became immediately consequential - leaving the US working through oversupply while London quietly drifted into structural scarcity.
In our new report, we unpack how the same capital surge produced such divergent outcomes, why a significant pipeline of consented UK schemes has effectively stalled, and why the next wave of occupier demand is not hypothetical - it is already funded.
The question the report leaves the reader with is a sharp one: the sector will recover. The only thing that remains to be decided is who will be positioned when it does.
Download the full e-Paper via below link:
Comments